Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of HK inno.N.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
HK inno.N
korearepublicofnew Flag
Country
Country
South Korea
Address
Address
(04551) 100, Eulji-ro, Jung-gu, Seoul
Telephone
Telephone
+82-2-6477-0000
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

As part of this agreement, the companies may open up a discussion on further developments, including clinical development and commercialization, if they succeed in discovering CAR-NK cell product candidates and producing non-clinical samples.


Lead Product(s): Allogeneic CAR-NK Cell Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

Recipient: Gicell

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

With the MOU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.


Lead Product(s): Exosome-loaded Antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Recipient: ILIAS Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under this partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan (CJ-12420), while Dr. Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories


Lead Product(s): Tegoprazan

Therapeutic Area: Gastroenterology Product Name: CJ-12420

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 11, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In the study, cohorts with 50 and 100 milligrams of K-CAB tablets showed superior therapeutic effect and safety in treating gastric ulcers than the group administered with 30 milligrams of Lansoprazole.


Lead Product(s): Tegoprazan

Therapeutic Area: Gastroenterology Product Name: K-CAB

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY